Full Press Release Details
dupixent dupilumab application for treatment of chronic spontaneous urticaria csu in adults and adolescents aged 12 years and older accepted for fda review.
REGN
dupixent dupilumab application for treatment of chronic spontaneous urticaria csu in adults and adolescents aged 12 years and older accepted for fda review
Key Takeaway: dupixent dupilumab application for treatment of chronic spontaneous urticaria csu in adults and adolescents aged 12 years and older accepted for fda review